Loading…
Loading…
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Successful pipeline development could substantially increase CRISPR's valuation. The upstart biotech has $2.36 billion to fund its expanding pipeline.
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m.
Creative Medical Technology (NASDAQ: CELZ - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings. Institutional and Insider Ownership 1.4% of Creative
CRISPR Therapeutics transitioned from speculative biotech to commercial stage with FDA approval of CASGEVY, validating its CRISPR/Cas9 platform. CRSP's pipeline targets multi-billion-dollar markets in cardiovascular, autoimmune, oncology, and diabetes, supported by a robust IP portfolio and major pharma partnerships. Current $5.6B market cap and $1.78B net cash position offer acquisition appeal, but most pipeline assets remain early stage and execution risks persist.
CRISPR Therapeutics' only approved product may experience increased demand. The biotech could also see significant clinical progress with some key candidates.
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.